Arcus Biosciences, Inc. RCUS
24.97
(0.09)
(0.36%)
as of 25 Sep
- Market cap
- $3.2B
- P/E
- 0.0×
Follow RCUS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(68.13%) | (63.26%) | (69.95%) | (90.82%) | |
| (30.64%) | (30.84%) | (34.28%) | (46.02%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(51.36%) | (43.26%) | (54.83%) | (77.44%) | |
Average Days of Receivables |
16.73 | 16.26 | 4.64 | 112.31 | |
Free Cash Flow per Share |
(4.36) | (4.51) | (3.89) | (3.76) | |
Free Cash Flow |
(464.00) | (484.00) | (488.00) | (474.00) | |
Capital Expenditures |
(2.00) | (2.00) | — | — | |
Piotroski F-Score |
1.00 | 0.00 | 1.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
(33.85%) | (28.17%) | (33.75%) | (37.41%) | |
Accounts Receivable Turnover |
17.78 | 15.94 | 26.22 | 4.59 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
209.58% | 211.74% | 221.61% | 424.79% | |
Selling, General and Administrative Expense of Revenue |
46.67% | 44.53% | 47.03% | 90.60% | |
Share Based Compensation of Revenue |
25.83% | 24.29% | 26.69% | 53.85% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.35 | 1.37 | 1.32 | 1.03 | |
Depreciation/Fixed assets |
(0.14) | (0.07) | (0.08) | 0.00 | |
Capex/Depreciation |
0.33 | 0.67 | 0.00 | — | |
Revenue per Share |
2.25 | 2.30 | 1.88 | 0.93 | |
Operating CF per Share |
(4.34) | (4.49) | (3.89) | (3.76) | |
Capex per Share |
(0.02) | (0.02) | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(142.08%) | (142.91%) | (156.36%) | (393.16%) |
Columns are period end dates